SCHEMBL10325159

SCHEMBL10325159

COC(=O)C1CC(OC2CCCCO2)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.37
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.35
FKBP1A P62942 1/20 0.35
UCHL1 P09936 3/20 0.35
USP30 Q70CQ3 1/20 0.35
EPHX1 P07099 1/20 0.34
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KLK7 P49862 1/20 0.34
PTPN1 P18031 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SCN4A P35499 1/20 0.33
EPHX2 P34913 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30181259 0.90 P2RX3 (0.37) HSD17B10NR1H2NR1H3SMN1; SMN2NPC1
SCHEMBL10239516 0.90 P2RX3 (0.37) HSD17B10NR1H2NR1H3SMN1; SMN2NPC1
SCHEMBL19942935 0.90 P2RX3 (0.37) HSD17B10NR1H2NR1H3SMN1; SMN2NPC1
SCHEMBL15273414 0.90 P2RX3 (0.37) HSD17B10NR1H2NR1H3SMN1; SMN2NPC1
SCHEMBL11322815 0.86 ALDH1A1 (0.36) SMN1; SMN2FKBP1ALMNAALDH1A1
SCHEMBL9313102 0.84 GPR119 (0.37) HSD17B10SMN1; SMN2EPHX1ALDH1A1
SCHEMBL9313113 0.84 GPR119 (0.37) HSD17B10SMN1; SMN2EPHX1ALDH1A1
SCHEMBL9313107 0.84 GPR119 (0.37) HSD17B10SMN1; SMN2EPHX1ALDH1A1
SCHEMBL10323879 0.81 ATM (0.38) HSD17B10NR1H2SMN1; SMN2EPHX1ALDH1A1
SCHEMBL9312962 0.81 ATM (0.40) HSD17B10SMN1; SMN2EPHX1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067949-B2 Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia ALBANY MOLECULAR RESEARCH, INC. (US) 2015-06-30 US disclosed
US-20120184531-A1 BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184531-A1 BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA HTR6, HTR5A, HTR2C HSD17B10 1286/4885NR1H2 460/4885NR1H3 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.